What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
Kish
Stephen J
SJ
D001921:Brain / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D002352:Carrier Proteins / Q000187:drug effects; D006213:Hallucinogens / Q000009:adverse effects*; D006801:Humans; D008562:Membrane Glycoproteins / Q000187:drug effects; D026901:Membrane Transport Proteins; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000009:adverse effects*; D009419:Nerve Tissue Proteins; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects; D050486:Serotonin Plasma Membrane Transport Proteins; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon
D002352:Carrier Proteins; D006213:Hallucinogens; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D011954:Receptors, Dopamine; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins; D018817:N-Methyl-3,4-methylenedioxyamphetamine